（於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 公告 控股股東股份質押解除 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」）日期為2024年5月20 日及2025年8月26日之公告（「該等公告」）。除另有界定外，本公告所用詞彙與該 等公告所界定者具有相同涵義。 誠如該等公告所披露，浦發銀行同意向廣州醫院授出高達人民幣13億元的非循環 信貸。根據授信額度協議的條款及條件，並為進一步擔保本公司於授信額度協議 項下的責任及提供額外擔保，於2025年8月26日，本公司控股股東（定義見香港聯 合交易所有限公司證券上市規則）北京泰和誠同意以浦發銀行為受益人質押本公 司35.6百萬股H股（「該質押」）。 本公司於2025年10月27日收到北京泰和誠的通知，該質押已於2025年10月2 ...

Core Viewpoint - Meizhong Jiahe has achieved a significant milestone by obtaining the Medical Device Registration Certificate for its AI-developed medical image processing software, marking a breakthrough in the field of medical imaging and digital healthcare [2] Group 1: Product Development and Certification - The software, named HXK-MAICOPPET-1-001, has been officially registered by the Beijing Drug Administration, indicating compliance with regulatory standards [2] - This software addresses clinical challenges associated with traditional PET-CT imaging, which is crucial for early cancer diagnosis and treatment evaluation [2][3] - The platform adheres to international DICOM3.0 standards and employs advanced image processing algorithms for multi-modal image fusion, lesion segmentation, and 3D reconstruction [2] Group 2: Clinical Impact and Efficiency - The software significantly reduces the workload for physicians by automating image processing and providing quantitative parameters for lesion assessment, thus enhancing diagnostic efficiency and consistency [3] - Although the system is currently an auxiliary tool and does not provide independent diagnostic capabilities, it optimizes workflow and alleviates the scarcity of quality medical resources [3] Group 3: Strategic Positioning and Future Growth - Meizhong Jiahe's strategy focuses on "technology leading tumor diagnosis and treatment," expanding its capabilities from treatment to diagnosis, thereby creating a comprehensive tumor management ecosystem [3] - The company aims to extend high-level imaging analysis capabilities to lower-tier cities and remote areas, promoting the effective sharing of quality medical resources [3][4] - With the integration of its software platform, Meizhong Jiahe is positioned to enhance its precision medical system, connecting proton therapy, imaging diagnosis, and intelligent decision-making [4]

Summary of Key Points Core Viewpoint - As of October 14, a total of 75 stocks reached their 52-week highs, with notable performances from Lihua Securities Holdings (08350), Deutsche Bank Tianxia (02418), and Chuangsheng Holdings (02680) [1]. 52-Week Highs - Lihua Securities Holdings (08350) achieved a closing price of 0.325, with a peak of 0.390, marking a high rate of 34.48% - Deutsche Bank Tianxia (02418) closed at 8.120, reaching a maximum of 8.990, with a high rate of 24.86% - Chuangsheng Holdings (02680) closed at 12.100, peaking at 12.350, with a high rate of 23.50% - Other notable stocks include Century United Holdings (01959) with a high rate of 20.97% and Silicon Xin Group (08349) with 14.38% [1]. 52-Week Lows - Hengda Group Holdings (03616) recorded a closing price of 0.345, with a low of 0.300, reflecting a decline rate of -11.76% - China Technology Industry Group (08111) reached a low of 0.085, with a decline rate of -8.89% - Other significant declines include Golden Leaf International Group (08549) at -8.06% and Changfeng Pharmaceutical (02652) at -4.90% [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 2. 股份 ...

Core Insights - The company, Meizhong Jiahe Medical Technology Development Group, has received academic recognition with its director, Professor Qian Zhaonan, being listed in the "Top 2% of Scientists Worldwide (2025)" by Stanford University and Elsevier, highlighting its research and clinical capabilities in the field of head and neck tumors, particularly nasopharyngeal carcinoma [1][2] Group 1: Academic Recognition - Professor Qian Zhaonan has been included in the prestigious list for six consecutive years, indicating his sustained academic influence and contributions to the field of oncology [1][2] - The list is recognized globally for its rigorous selection criteria, which focus on genuine academic contributions, thus enhancing the credibility of the recognition [1] Group 2: Clinical Impact - The recognition signifies that the company's research outcomes are being effectively translated into clinical practices, establishing a competitive edge in the market [2] - The hospital has developed a unique treatment system focusing on nasopharyngeal carcinoma while also covering multiple diseases, showcasing its innovative approaches in proton therapy [2] Group 3: Strategic Direction - The company emphasizes a strategy of "research-driven + international collaboration," which has been pivotal in attracting top talent and enhancing its research capabilities [3] - Future plans include increasing investment in research, particularly in proton therapy, immunotherapy, and artificial intelligence applications in treating nasopharyngeal carcinoma and other prevalent tumors [3]

Investment Rating - The report rates the automotive industry as "Positive" [4] Core Insights - The adjustment of the vehicle replacement policy will slightly weaken demand, but the reduction in vehicle purchase tax will promote early purchases, leading to a competitive demand scenario in Q4. As of September 10, 2025, the number of applications for vehicle replacement reached 8.3 million, indicating a significant policy-driven effect. Despite the adjustments in the replacement policy, the pressure from the tax reduction is expected to encourage consumers to purchase new energy vehicles earlier. The report forecasts that China's new energy vehicle sales will reach 16.25 million units in 2025, representing a year-on-year growth of approximately 26% [2][18]. Monthly Focus - The adjustment of the vehicle replacement policy has increased application difficulty. Since June, applications for vehicle replacement have been suspended due to the exhaustion of funds, but recent funding has led to adjustments in the policy across various regions. The adjustments mainly include changes in application methods and subsidy standards, with some regions reducing the subsidy amount per vehicle [14][15]. - There is a significant funding gap for Q4, as the distribution of funds does not account for seasonal consumption patterns. The central government will allocate 69 billion yuan for Q4, which is the same as Q3, but the demand for vehicle consumption is typically stronger in the second half of the year, leading to an amplified funding gap for Q4 [16][17]. Key Data Tracking - In August, the sales of new energy vehicles in China reached 1.4 million units, a year-on-year increase of 27%. The penetration rate for new energy vehicles was 49%, remaining stable compared to the previous month. However, the sales of plug-in hybrid vehicles (PHEVs) experienced a decline for two consecutive months, primarily due to pressure on sales from major manufacturers [20][28]. - The report highlights that commercial vehicles and exports continue to maintain high growth rates, with new energy commercial vehicle sales in August reaching 70,000 units, a year-on-year increase of 52% [34][35]. - The report also notes that the export of new energy vehicles has been robust, with August exports reaching 224,000 units, a year-on-year increase of 104% [46][48]. Industry and Company Changes - The report indicates progress in the overseas production capacity of automotive companies, with several manufacturers establishing production bases in regions like Brazil and Austria. Additionally, companies like Chery and HeSai have listed on the Hong Kong stock exchange, while Dongfeng Group plans to privatize and spin off its Lantu brand to maintain its listing status [3][45].

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2025, representing a 15% increase compared to the same period last year[11]. - The company expects a revenue guidance of RMB 1.1 billion for the full year 2025, reflecting a projected growth of 10%[11]. - Revenue decreased by 8.3% from RMB 219.0 million for the six months ended June 30, 2024, to RMB 200.9 million for the six months ended June 30, 2025[17]. - Hospital business revenue increased by 11.2% from RMB 137.8 million to RMB 153.2 million during the same period[17]. - The company reported a total revenue of RMB 200.9 million, with RMB 153.2 million from medical equipment and services, and RMB 47.7 million from hospital operations[185]. - Total revenue for the six months ended June 30, 2025, was RMB 200,903,000, a decrease from RMB 218,988,000 in the same period of 2024, representing a decline of approximately 8.3%[192]. Operational Developments - New product launches include a telemedicine platform expected to enhance patient engagement and streamline services, with an anticipated launch date in Q3 2025[11]. - The company is expanding its market presence by opening three new clinics in tier-2 cities, aiming to increase accessibility to healthcare services[11]. - The group operates 4 self-owned medical institutions and has 1 under construction, focusing on high-end oncology medical services[18]. - Guangzhou Taihe Cancer Hospital, with a planned area of over 100,000 square meters, is set to provide comprehensive cancer care services[19]. - Shanghai Taihe Cheng Cancer Hospital, under construction, will cover nearly 160,000 square meters and collaborate with MD Anderson Cancer Center[20]. - The group has established a light asset business model for medical equipment and software services, targeting lower-tier cities[22]. Research and Development - Research and development investments have increased by 25%, focusing on advanced medical technologies and treatment protocols[11]. - The group has initiated a research project on the mechanism of NOS1 regulation in nasopharyngeal carcinoma, showcasing its regional influence in medical research[31]. - In the first half of 2025, the group published eight SCI academic papers and has two invention patents under review, showcasing its strength in tumor treatment and technological innovation[33]. - The company achieved a significant breakthrough in AI medical applications by developing the world's first large language model specifically for proton therapy, improving clinical efficiency across multiple dimensions[41]. Financial Stability and Cost Management - The company has implemented cost-control measures that are expected to reduce operational expenses by 5% in the next fiscal year[11]. - Total cost of revenue decreased by 20.9% from RMB 253.5 million to RMB 200.5 million for the same periods[53]. - Employee benefits expenses decreased from RMB 58.99 million (23.3%) in 2024 to RMB 49.08 million (24.5%) in 2025[54]. - Selling and distribution expenses decreased by 15.4% from RMB 25.0 million for the six months ended June 30, 2024, to RMB 21.1 million for the six months ended June 30, 2025, due to reduced employee costs and promotional expenses[63]. - Administrative expenses decreased by 30.0% from RMB 79.1 million for the six months ended June 30, 2024, to RMB 55.3 million for the six months ended June 30, 2025, primarily due to lower employee costs and listing expenses[64]. Market and Strategic Initiatives - The company is exploring potential acquisitions to enhance its service offerings and market share, with discussions ongoing with two target companies[11]. - A strategic partnership with a leading pharmaceutical company has been established to co-develop innovative treatment solutions[11]. - The company aims to expand its market presence in the trillion-level oncology market by leveraging its expertise and first-mover advantage in oncology treatment[42]. - The aging population and rising cancer incidence present both challenges and opportunities for the company, particularly in early screening and intervention, precision diagnosis and treatment, and comprehensive management[43]. Shareholder and Governance - The company has adopted corporate governance principles to enhance transparency and accountability to all shareholders, complying with applicable codes throughout the reporting period[127]. - As of June 30, 2025, Dr. Yang held 26.16% of the company's total equity through controlled entities, and 8.69% in H-shares[131]. - The company’s controlling shareholder, Shanghai Medical Star, has pledged a total of 96,137,318 domestic shares as collateral for a loan not exceeding RMB 500 million, which accounts for approximately 13.08% of the total issued share capital as of June 30, 2025[144]. - The company’s board of directors confirmed their responsibility for preparing the financial statements for the six months ending June 30, 2025, ensuring compliance with regulatory requirements[149]. Cash Flow and Liquidity - Cash and cash equivalents increased by 52.4% from RMB 111.5 million as of June 30, 2024, to RMB 170.0 million as of June 30, 2025, primarily due to a decrease in cash used in operating and investing activities[80]. - Net cash used in operating activities decreased from RMB 178.8 million for the six months ended June 30, 2024, to RMB 60.4 million for the six months ended June 30, 2025, mainly due to cost reduction measures[82]. - The company had unused credit facilities of approximately RMB 1.555 billion as of June 30, 2025, indicating strong liquidity[182]. - The financing activities generated a net cash inflow of RMB 51.2 million, a decrease from RMB 714.1 million in the previous year, primarily due to reduced bank borrowings[182]. Losses and Impairments - Net loss decreased by 1.0% from RMB 202.0 million to RMB 200.0 million[17]. - Adjusted net loss increased by 24.2% from RMB 161.1 million to RMB 200.0 million[17]. - The company reported a net loss before tax of RMB (204,522,000) for the six months ended June 30, 2025, compared to a loss of RMB (193,673,000) in the same period of 2024[189]. - The company recorded a loss attributable to owners of RMB 176.6 million for the same period, with a net cash outflow from investing activities of RMB 25.3 million, significantly improved from RMB 464.3 million in the previous year[179].

Core Viewpoint - The company has entered into a financing agreement with Beijing Daxing Development Financing Leasing Co., Ltd., securing up to 20 million RMB in funding to support its future business development [1] Group 1: Financing Agreement - The financing amount is capped at 20 million RMB, with a term of three years and an interest rate of 4.19% [1] - The partnership with Daxing Development Leasing aims to enhance the company's financing channels and diversify its funding sources [1] Group 2: Strategic Implications - Collaborating with a specialized financing leasing company will help the company meet its funding needs for future business growth [1] - This partnership is expected to establish long-term cooperative relationships with professional institutions in the industry, laying a foundation for future collaborations [1]

Core Viewpoint - The company has entered into a business cooperation agreement with Beijing Daxing Development Financing Leasing Co., Ltd., securing financing of up to 20 million RMB with a three-year term and an interest rate of 4.19% [1] Group 1: Financing Details - The financing amount agreed upon is not to exceed 20 million RMB [1] - The financing term is set for three years with an interest rate of 4.19% [1] Group 2: Partner Profile - Beijing Daxing Development Financing Leasing Co., Ltd. is a financing leasing platform under the state-owned Beijing Daxing Development State-owned Capital Investment Operation Co., Ltd. [1] - The leasing company specializes in innovative leasing solutions across various sectors, including new infrastructure, renewable energy, biomedicine, and high-end manufacturing [1] Group 3: Strategic Implications - The collaboration with a professional financing leasing company will help the company expand its financing channels and diversify its funding sources [1] - This partnership is expected to provide more assurance for the company's future funding needs and establish long-term cooperative relationships within the industry [1]

Core Viewpoint - The company has entered into a financing agreement with Beijing Daxing Development Financing Leasing Co., Ltd., securing up to 20 million RMB in funding to support its future business development [1] Group 1: Financing Agreement - The financing amount is capped at 20 million RMB, with a term of three years and an interest rate of 4.19% [1] - The partnership with Daxing Development Leasing aims to enhance the company's financing channels and diversify its funding sources [1] Group 2: Strategic Implications - Collaborating with a specialized financing leasing company will help the company meet its funding needs for future business growth [1] - This partnership is expected to establish a long-term cooperative relationship with industry professionals, laying the groundwork for future collaborations [1]